Tag:
Bayer
Latest Headlines
Latest Headlines
J&J loses key FDA panel vote on Xarelto
The balloting turned against J&J after 6 of 10 outside experts concluded that the risk of bleeding and doubts about its pivotal data prevented them from endorsing an approval for preventing heart attacks and strokes among patients with heart problems.
NICE nod for Xarelto as FDA panel mulls new use
The advisory panel is weighing evidence for a new, potentially lucrative use in patients with acute coronary syndrome.
Bayer's Nexavar falters in another lung cancer trial
Nexavar did deliver "an improvement" in progression-free survival, the companies said, but that was the study's secondary endpoint.
FDA review backs Xarelto for big new use in ACS patients
The anticoagulant won a thumbs-up from FDA reviewers ahead of Wednesday's advisory panel meeting, where FDA experts will weigh a lucrative new indication.
OncoMed offers $115M IPO bet on cancer stem cell work
A year after scoring a $20 million milestone from Bayer, OncoMed Pharmaceuticals is preparing to see if it can generate enough excitement from investors for its cancer stem cell work to support a $115 million IPO.
Indian gov't probes drug regulator after scathing review
Days after a parliamentary report noted shoddy oversight of approvals, the Indian government has mounted an investigation into the alleged misdeeds. Meanwhile, big names in biopharma have surfaced in the sea of allegations.
Report: Bayer contemplates sale of blood glucose meter business
This just in: Bayer is reportedly talking with potential buyers of its blood glucose meters business.
Bayer slams Indian government, Cipla on Nexavar copies
Since the Indian government yanked its exclusivity on the cancer drug, the German company is fighting back.
India's Cipla puts fire-sale prices on cancer drugs
Indian genericsmaker Cipla will sell its copies of cancer drugs for a fraction of their branded counterparts.
Interested shoppers prompt Warner to weigh sale options
Warner Chilcott is the latest drugmaker to stir up the M&A pot. The company is looking at its options, including a possible sale, Bloomberg reports.
